Thirty-Day Outcomes of Young and Middle-Aged Adults Admitted with Severe COVID-19 in Uganda: A Retrospective Cohort Study
Kyagambiddwa et al.,
Thirty-Day Outcomes of Young and Middle-Aged Adults Admitted with Severe COVID-19 in Uganda: A Retrospective..,
Infection and Drug Resistance, doi:10.2147/idr.s405256
This study includes
zinc and vitamin C.
risk of death, 50.0% lower, HR 0.50, p = 0.06, adjusted per study, multivariable, Cox proportional hazards.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Kyagambiddwa et al., 11 May 2023, retrospective, Uganda, peer-reviewed, mean age 39.0, 15 authors, study period May 2020 - August 2022.
Contact:
tonnykyagambiddwa97@gmail.com, enuwagira@must.ac.ug.
Abstract: Infection and Drug Resistance
Dovepress
open access to scientific and medical research
Open Access Full Text Article
ORIGINAL RESEARCH
Infection and Drug Resistance
For personal use only.
Thirty-Day Outcomes of Young and Middle-Aged
Adults Admitted with Severe COVID-19 in
Uganda: A Retrospective Cohort Study
Tonny Kyagambiddwa 1,*, Timothy Mwanje Kintu 1,*, Emmanuel Miiro 1,*, Franchesca Nabalamba1,
Gloria Suubi Asiimwe1, Anne Marion Namutebi2, Fardous C Abeya3, Boniface A Lumori3, Isaac Ijuka4,
Rose K Muhindo1,3, Andrew Mutekanga 1,3, Richard Musinguzi 5, Francis Natuhwera6, Joseph Ngonzi1,7,
Edwin Nuwagira 3,8
1
Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda; 2Kabale Regional Referral Hospital, Kabale, Uganda;
Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda; 4Mayanja Memorial Hospital, Mbarara, Uganda; 5Masaka
Regional Referral Hospital, Masaka, Uganda; 6Fort Portal Regional Referral Hospital, Fort Portal, Uganda; 7Department of Obstetrics and Gynecology,
Mbarara University of Science and Technology, Mbarara, Uganda; 8Tuberculosis Treatment Unit, Mbarara Regional Referral Hospital, Mbarara, Uganda
3
*These authors contributed equally to this work
Correspondence: Tonny Kyagambiddwa; Edwin Nuwagira, Mbarara University of Science and Technology, Tel +256782980116; +256779096887,
Email tonnykyagambiddwa97@gmail.com; enuwagira@must.ac.ug
Background: There is scarcity of data regarding young and middle-aged adults hospitalized with severe Corona Virus Disease 2019
(COVID-19) in Africa. In this study, we describe the clinical characteristics and 30-day survival among adults aged 18 to 49 years
admitted with severe COVID-19 in Uganda.
Methods: We reviewed treatment records of patients admitted with severe COVID-19 across five COVID-19 treatment units (CTU)
in Uganda. We included individuals aged 18 to 49 years, who had a positive test or met the clinical criteria for COVID-19. We defined
severe COVID-19 as having an oxygen saturation <94%, lung infiltrates >50% on imaging and presence of a co-morbidity that
required admission in the CTU. Our main outcome was the 30-day survival from the time of admission. We used a Cox proportional
hazards model to determine the factors associated with 30-day survival at a 5% level of significance.
Results: Of the 246 patient files reviewed, 50.8% (n = 125) were male, the mean ± (standard deviation) age was 39 ± 8 years, majority
presented with cough, 85.8% (n = 211) and median C-reactive protein (interquartile range) was 48 (47.5, 178.8) mg/L. The 30-day
mortality was 23.9% (59/246). At admission, anemia (hazard ratio (HR): 3.00, 95% confidence interval (CI), 1.32–6.82; p = 0.009) and
altered mental state (GCS <15) (HR: 6.89, 95% CI: 1.48–32.08, p = 0.014) were significant predictors of 30-day mortality.
Conclusion: There was a high 30-day mortality among young and middle-aged adults with severe COVID-19 in Uganda. Early
recognition and targeted management of anemia and altered consciousness are needed to improve clinical outcomes.
Keywords: COVID-19, Uganda, mortality, young and middle-aged adults
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit